EUVIMEDEUVIMED entdecken
Editorial

Barzolvolimab: Targeting the effector cell in chronic spontaneous urticaria

Matthew P Giannetti

Journal of Allergy and Clinical Immunology · 2026-11 · 158 (5) · 1235-1237

DOI: 10.1016/j.jaci.2026.08.002 ↗

Kurz gefasst

Editorial in der Zeitschrift Journal of Allergy and Clinical Immunology, 2026-11. Verfasst von Matthew P Giannetti. Beteiligte Einrichtung: Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Mass; Harvard Medical School, Boston, Mass. Electronic address: mg…. Die Arbeit nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Chronic spontaneous urticariabarzolvolimabmast cellstryptase

Autor:innen und Institutionen

  • Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Mass; Harvard Medical School, Boston, Mass. Electronic address: mgiannetti@bwh.harvard.edu.

Zitieren

APA

Giannetti, M. P. (2026). Barzolvolimab: Targeting the effector cell in chronic spontaneous urticaria. Journal of Allergy and Clinical Immunology, 158(5), 1235-1237. https://doi.org/10.1016/j.jaci.2026.08.002

Vancouver

Giannetti MP. Barzolvolimab: Targeting the effector cell in chronic spontaneous urticaria. Journal of Allergy and Clinical Immunology. 2026;158(5):1235-1237. doi:10.1016/j.jaci.2026.08.002

BibTeX
@article{Giannetti2026,
  author = {Giannetti, Matthew P},
  title = {Barzolvolimab: Targeting the effector cell in chronic spontaneous urticaria},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2026},
  volume = {158},
  number = {5},
  pages = {1235--1237},
  doi = {10.1016/j.jaci.2026.08.002}
}
Kostenlos starten →